Doria (risperidone extended release) / ROVI Pharmaceuticals Laboratories |
PRISMA-1, NCT01788774: Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths |
|
|
| Completed | 1 | 36 | Europe, RoW | Risperidone ISM 50 mg, Risperidone ISM 75 mg, Risperidone ISM 100 mg | Rovi Pharmaceuticals Laboratories | Schizophrenia, Schizoaffective Disorder | 02/14 | 02/14 | | |
NCT01320410: Pharmacokinetics, Safety, and Tolerance Study of Single Dose Administration of Risperidone ISM® |
|
|
| Completed | 1 | | Europe | ISM® | Rovi Pharmaceuticals Laboratories | Healthy | | | | |
| Completed | 1 | 81 | US | Risperidone ISM® 100 mg | Rovi Pharmaceuticals Laboratories | Schizophrenia | 03/19 | 04/19 | | |
| Completed | 1 | 80 | US | Risperidone ISM® 100 mg, Risperdal 4mg Tablet | Rovi Pharmaceuticals Laboratories | Schizophrenia | 09/21 | 09/21 | | |
QUARTZ, NCT06276361: Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia |
|
|
| Recruiting | 1 | 100 | RoW | Oral risperidone; QUAR F1/2, Dose 1 - Gluteal, Oral risperidone; QUAR F1/2, Dose 2 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Deltoids | Rovi Pharmaceuticals Laboratories | Schizophrenia | 05/26 | 05/26 | | |